Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· January 5, 2026

Lucid, Nuro, and Uber Unveil Global Robotaxi at CES, Announce Autonomous On-Road Testing

View original at finance.yahoo.com
Lucid, Nuro, and Uber Unveil Global Robotaxi at CES, Announce Autonomous On-Road Testing Industry's most luxurious robotaxi, offering riders an unprecedented in-cabin experience Autonomous on-road testing, led by Nuro, began in December, marking an important milestone in service validation and path to launch later in 2…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Partnership will bring state-of-the-art robotaxi to market later in 2026

    80% confidence

  • Uber has facilitated more than 681 billion trips since 2010

    80% confidence

  • Uber's mission is to create opportunity through movement

    80% confidence

  • Robotaxi program with Uber and Nuro is key part of how Lucid is leveraging technology to create more sustainable future of mobility

    80% confidence

  • Lucid's engineering, range and interior comfort combined with Nuro's technology and Uber's scale creates an experience like no other

    80% confidence

  • Autonomous on-road testing is part of Nuro's safety and validation framework honed over years of commercial autonomous deployments

    80% confidence

  • Partnership brings together Nuro's proven level 4 autonomy, Lucid's advanced vehicle architecture, and Uber's global reach to build robotaxi service designed for real-world operations and long-term growth

    80% confidence

  • The debut of production intent robotaxi is a significant milestone on path to delivering autonomy at scale

    80% confidence

  • Partnership combines leading expertise in electric vehicles, autonomy, and ridehailing to build unique option for affordable and scalable autonomous rides

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com